These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7410445)

  • 21. A direct plaque assay for Mount Elgon bat virus.
    Gomwalk NE
    J Virol Methods; 1980; 1(4):201-8. PubMed ID: 7276123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improvement in potency assay of measles-mumps-rubella trivalent vaccine: interference between components and measures for its elimination.
    Umino Y; Saito S; Fukuda A; Hishiyama M; Sugiura A
    J Virol Methods; 1990 Feb; 27(2):159-68. PubMed ID: 1690744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The significance for epidemiological studies anti-measles antibody detection examined by enzyme immunoassay (EIA) and plaque reduction neutralization test (PRNT).
    Siennicka J; Częścik A; Trzcińska A
    Przegl Epidemiol; 2014; 68(3):417-20, 527-9. PubMed ID: 25394302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced yields of measles virus from cultured cells.
    Scott JV; Choppin PW
    J Virol Methods; 1982 Nov; 5(3-4):173-9. PubMed ID: 7153305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A simplified plaque assay for respiratory syncytial virus--direct visualization of plaques without immunostaining.
    McKimm-Breschkin JL
    J Virol Methods; 2004 Sep; 120(1):113-7. PubMed ID: 15234816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies on a measles virus variant inducing persistent infections in cultured cells.I. Isolation and characterization of plaque purified virus clones.
    Chiarini A; Sinatra A; Ammatuna P; Di Stefano R
    Arch Virol; 1976; 52(1-2):47-58. PubMed ID: 826238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defective interfering particles produced during the replication of measles virus.
    Hall WW; Martin SJ; Gould E
    Med Microbiol Immunol; 1974; 160(2-3):155-64. PubMed ID: 4216759
    [No Abstract]   [Full Text] [Related]  

  • 28. Properties of a measles virus neuropathic for rhesus monkeys.
    O'Brien TC; Albrecht P; Tauraso NM; Burns GR
    Arch Gesamte Virusforsch; 1972; 39(1):228-39. PubMed ID: 4629001
    [No Abstract]   [Full Text] [Related]  

  • 29. Genetic and antigenic characterisation of the haemagglutinin protein of measles virus strains recently circulating in the UK.
    Jin L; Knowles WA; Rota PA; Bellini WJ; Brown DW
    Virus Res; 1998 May; 55(1):107-13. PubMed ID: 9712517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thermal inactivation of different measles virus strains.
    Klamm H; Pollex G; Henning U
    Acta Virol; 1991 Apr; 35(2):200-2. PubMed ID: 1681719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenesis of vaccine strains of measles virus in suckling hamsters.
    Mirchamsy H; Razavi J; Ahurai P
    Acta Virol; 1972 Jun; 16(1):77-9. PubMed ID: 4400679
    [No Abstract]   [Full Text] [Related]  

  • 32. A carboxymethyl-cellulose plaque assay for feline calicivirus.
    Escobar-Herrera J; Medina-Ramírez FJ; Gutiérrez-Escolano AL
    J Virol Methods; 2007 Dec; 146(1-2):393-6. PubMed ID: 17719097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Measles virus: induced transfer of biological properties.
    Weil ML; Imagawa DT
    Arch Gesamte Virusforsch; 1972; 39(4):344-52. PubMed ID: 4630532
    [No Abstract]   [Full Text] [Related]  

  • 34. The cellular stress response increases measles virus-induced cytopathic effect.
    Vasconcelos D; Norrby E; Oglesbee M
    J Gen Virol; 1998 Jul; 79 ( Pt 7)():1769-73. PubMed ID: 9680141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Titration and stability tests for antimeasles vaccine].
    Ayala-González M
    Bol Med Hosp Infant Mex; 1990 Jul; 47(7):512-5. PubMed ID: 2206418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Laboratory methods for assessing vaccine potency retained in aerosol outputs from nebulizers: application to World Health Organization measles aerosol project.
    Cohen BJ; Parry RP; Andrews N; Bennett AM; Dennis JH
    Vaccine; 2008 Jun; 26(27-28):3534-9. PubMed ID: 18490082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The plaque-neutralization test as a measure of prior exposure to measles virus.
    Orenstein WA; Albrecht P; Herrmann KL; Bernier R; Bart KJ; Rovira EZ
    J Infect Dis; 1987 Jan; 155(1):146-9. PubMed ID: 3794399
    [No Abstract]   [Full Text] [Related]  

  • 38. Development and evaluation of an automatable focus reduction neutralisation test for the detection of measles virus antibodies using imaging analysis.
    Terletskaia-Ladwig E; Enders G; Meier S; Dietz K; Enders M
    J Virol Methods; 2011 Dec; 178(1-2):124-8. PubMed ID: 21939689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimation of the number of infectious measles viruses in live virus vaccines using quantitative real-time PCR.
    Schalk JA; van den Elzen C; Ovelgönne H; Baas C; Jongen PM
    J Virol Methods; 2004 May; 117(2):179-87. PubMed ID: 15041215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantification of RSV Infectious Particles by Plaque Assay and Immunostaining Assay.
    Jorquera PA; Tripp RA
    Methods Mol Biol; 2016; 1442():33-40. PubMed ID: 27464685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.